Microenvironment modulation and enhancement of antilymphoma therapy by the heparanase inhibitor roneparstat
Sign Up to like & getrecommendations! Published in 2018 at "Hematological Oncology"
DOI: 10.1002/hon.2466
Abstract: The standard management of diffuse large B‐cell lymphoma (DLBCL) relies on the chemotherapy combination including cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP). Although the introduction of anti‐CD20 monoclonal antibody rituximab with CHOP chemotherapy has demonstrated a… read more here.
Keywords: combination; heparanase; inhibitor roneparstat; heparanase inhibitor ... See more keywords